| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 09/18/2002 | EP0952837B1 Use of mixtures of active substances, containing phytostenols and/or phytostenol esters and potentiators, for the production of hypocholesteremic agents |
| 09/18/2002 | EP0921808B1 Non-aqueous polar aprotic peptide formulations |
| 09/18/2002 | EP0915684A4 Material for buffered resorbable internal fixation devices and method for making same |
| 09/18/2002 | EP0910388B1 Pharmaceutical preparation for the treatment of gastritis, reflux oesophagitis, duodenitis, dyspepsia and ulcer disease |
| 09/18/2002 | EP0823889B1 1,3-propane diol derivatives as bioactive compounds |
| 09/18/2002 | EP0810880B1 Pharmaceuticals and assays using enzyme subunits |
| 09/18/2002 | EP0724432B1 Methods and compositions for microencapsulation of antigens for use as vaccines |
| 09/18/2002 | CN1370241A Process for producing Lycopen |
| 09/18/2002 | CN1370232A Methods for making APO-2 ligand using divalent metal ions |
| 09/18/2002 | CN1370201A Polymeric compsn. for solubilizing poorly water soluble drugs and process for prepn. thereof |
| 09/18/2002 | CN1370195A Rapidly decomposing chitosan-based pellets |
| 09/18/2002 | CN1370181A Effectors of dipeptidyl peptidase IV for topical use |
| 09/18/2002 | CN1370133A Polytype Mg-Al hydrotalcite |
| 09/18/2002 | CN1370084A Tissue augmentation material and methods |
| 09/18/2002 | CN1370082A Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| 09/18/2002 | CN1370072A Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
| 09/18/2002 | CN1370068A Pharmaceutical agent comprising benzamide derivative as active ingredient |
| 09/18/2002 | CN1370065A Pharmaceutical prepn. |
| 09/18/2002 | CN1369310A Coating agent for treating tinea and eczema |
| 09/18/2002 | CN1090935C Pharmaceutical compsn. of piperidnoalkanol compounds |
| 09/18/2002 | CN1090918C Silicone compsns. |
| 09/17/2002 | US6451995 Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods |
| 09/17/2002 | US6451986 Conjugating a protein with polyethylene glycol (peg), by deleting amino residue(s); for example, replacing protein arginine residues with lysine residues that provide a peg attachment site; bioactivity |
| 09/17/2002 | US6451983 Tumor necrosis factor antibodies |
| 09/17/2002 | US6451980 Antibody testing; obtain sample, incubate with binding particles, detect signal |
| 09/17/2002 | US6451968 Hoogsteen type base pairing in triplex motif; diagnosis; heat resistance; detection of point mutations, restriction enzyme sites, and transcription inhibition |
| 09/17/2002 | US6451848 Compositions and methods comprising morphine gluconate |
| 09/17/2002 | US6451773 Composition for treating acneiform eruption containing: (a) a chitosan having a molecular weight ranging from about 500,000 to about 5,000,000 g/mole and a degree of deacylation greater than 80%; (b) an acid-form active ingredient for treating acne |
| 09/17/2002 | US6451772 Biopolymer salts with low endotoxin levels, biopolymer compositions thereof and methods of making the same |
| 09/17/2002 | US6451527 A method of selecting internalizing ligands displayed on a genetic package from a library of ligand displaying genetic packages, comprising: contacting a library of ligand displaying genetic packages with a cell and detection of |
| 09/17/2002 | US6451350 Coating with aqueous ethyl cellulose and lipophilic plasticizing diester; drying |
| 09/17/2002 | US6451348 Method of manufacturing porous matrix-type controlled release systems using emulsion technique |
| 09/17/2002 | US6451347 Complexing oxidized or deamidated human growth hormone with metal; precipitation, isolation |
| 09/17/2002 | US6451346 Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents |
| 09/17/2002 | US6451337 Chitosan-based nitric oxide donor compositions |
| 09/17/2002 | US6451325 Vaccines; oil in water emulsion and detergent; lipophilic muramyl dipeptide immunostimulant; free of ethylene oxide-propylene oxide block copolymer |
| 09/17/2002 | US6451317 Immunogenic conjugates comprising a Group B meningococcal porin and an H influenzae polysaccharide |
| 09/17/2002 | US6451314 MHC conjugates useful in ameliorating autoimmunity |
| 09/17/2002 | US6451313 Heterotetramer; expression vectors encoding heavy and light chains; viricides |
| 09/17/2002 | US6451312 Diagnosis, imaging; induction of endothelial cell surface antigens |
| 09/17/2002 | US6451310 Preventing t cell activation of b cells by administering antibody cabable of binding protein recognized by monoclonal antibody 5c8 |
| 09/17/2002 | US6451302 Parenteral water-miscible non-intensely colored injectable composition of non-steroidal anti-inflammatory drugs |
| 09/17/2002 | US6451289 Albuterol formulations |
| 09/17/2002 | US6451287 An amphiphilic fluorinated block copolymer having at least one lyophobic block and at least one lyophilic block, wherein each of said blocks are formed from monomers |
| 09/17/2002 | US6451286 Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds |
| 09/17/2002 | US6451285 Mixture of drug, propellant and solvent |
| 09/17/2002 | US6451122 Dextrose in powder form and a process for the preparation thereof |
| 09/17/2002 | CA2222304C Pharmaceutical amiodarone composition for parenteral delivery |
| 09/17/2002 | CA2182576C Bilayer preparations |
| 09/17/2002 | CA2098525C Oral composition |
| 09/17/2002 | CA2020431C Aqueous liquid eyedrop composition |
| 09/17/2002 | CA2019095C Bio-adhesive composition |
| 09/16/2002 | CA2376843A1 Inhomogeneous silicas as carrier material |
| 09/12/2002 | WO2002070725A1 Carrier chimeric proteins, targeted carrier chimeric proteins and preparation thereof |
| 09/12/2002 | WO2002070594A2 A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge |
| 09/12/2002 | WO2002070590A2 Hydrogel attached to backing and method for making same |
| 09/12/2002 | WO2002070549A2 Chimeric polypeptides of serum albumin and uses related thereto |
| 09/12/2002 | WO2002070496A1 Nitric oxide donors based on metallic centres |
| 09/12/2002 | WO2002070438A2 Compositions for delivering bisphosphonates |
| 09/12/2002 | WO2002070070A2 Compositions having improved bioavailability of eletriptan |
| 09/12/2002 | WO2002070029A2 Porous beta-tricalcium phosphate granules and methods for producing same |
| 09/12/2002 | WO2002070017A1 Siderophore antibiotic conjugates with tetra- or hexadentate iron chelators on the basis of amino acids or peptides, method for producing them and the use thereof |
| 09/12/2002 | WO2002070016A2 Catecholate beta-lactam conjugates, method for producing the same and the use thereof |
| 09/12/2002 | WO2002070015A2 Polydimethylsiloxane preparation for nail, cartilage, bone and joint disorders |
| 09/12/2002 | WO2002070014A1 Compositions comprising an o/w emulsion containing conjugated linoleic acid |
| 09/12/2002 | WO2002070000A1 Recombinant gelatin-like proteins for use as plasma expanders |
| 09/12/2002 | WO2002069999A1 Stable aqueous solutions of granulocyte macrophage colony-stimulating factor |
| 09/12/2002 | WO2002069993A1 Pharmaceutical composition made of cannabis extracts |
| 09/12/2002 | WO2002069983A1 Amphotericin b aqueous composition |
| 09/12/2002 | WO2002069967A1 Percutaneous absorption compositions |
| 09/12/2002 | WO2002069966A1 Injectable pharmaceutical composition for treatment and reversal of erectile dysfunction |
| 09/12/2002 | WO2002069962A1 Compositions and preparations of silymarin complex with the improved bioavailability |
| 09/12/2002 | WO2002069957A1 Fenofibrate-containing composition |
| 09/12/2002 | WO2002069945A2 Novel medicament compositions on the basis of anticholinergics and pde iv inhibitors |
| 09/12/2002 | WO2002069944A2 Novel medicament compositions based on anticholinergics and on nk1 receptor antagonists |
| 09/12/2002 | WO2002069942A1 Adhesive patch |
| 09/12/2002 | WO2002069941A1 Transdermal therapeutic system for the administration of partial dopamine-d2 agonists |
| 09/12/2002 | WO2002069940A2 Highly flexible transdermal therapeutic system having nicotine as active substance |
| 09/12/2002 | WO2002069939A2 Taste masked pharmaceutical compositions |
| 09/12/2002 | WO2002069938A1 Production of nanoparticles from methyl vinyl ether copolymer and maleic anhydride for the administration of hydrophilic pharmaceuticals, more particularly of puric and pyrimidinic bases |
| 09/12/2002 | WO2002069937A1 Compounds and compositions for delivering active agents |
| 09/12/2002 | WO2002069933A1 Tablets quickly disintegrating in oral cavity |
| 09/12/2002 | WO2002069932A1 Foaming compositions |
| 09/12/2002 | WO2002069930A1 Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| 09/12/2002 | WO2002069906A2 Compounds and methods for the treatment of urogenital disorders |
| 09/12/2002 | WO2002063010A9 Method of producing recombinant antibodies against tumors |
| 09/12/2002 | WO2002053197A3 Hot melt adhesives for dermal application |
| 09/12/2002 | WO2002053175A3 Use of botulinum toxin for treatment of articular pathologies |
| 09/12/2002 | WO2002051865A3 Proteinic antigens inducing antibodies neutralising hiv virus |
| 09/12/2002 | WO2002050100A3 Diaminodicarboxylic acid: peptide-based gemini surfactant compounds used for drug delivery |
| 09/12/2002 | WO2002032375A8 Uses of monoclonal antibody 8h9 |
| 09/12/2002 | WO2002022680A3 Site-specific, antibody-mediated activation of proapoptotic cytokine: amaice (antibody-mediated apoptosis inducing cytokine) |
| 09/12/2002 | WO2002022132A3 Novel topical oestroprogestational compositions with systemic effect |
| 09/12/2002 | WO2002007748A3 Stimulation of cartilage growth with agonists of the non-proteolytically activated thrombin receptor |
| 09/12/2002 | WO2001093914A3 Multivalent platform molecules comprising high molecular weight polyethylene oxide |
| 09/12/2002 | WO2001089558A3 Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states |
| 09/12/2002 | WO2001089520A3 Dehydroascorbic acid formulations and uses thereof |
| 09/12/2002 | WO2001085218A3 Acylated cyclodextrin guest inclusion complexes |
| 09/12/2002 | WO2001083529A3 Immunoadhesin for the prevention of rhinovirus infection |
| 09/12/2002 | WO2001077360A3 Methods for ansamitocin production |